MGNX

Macrogenics Inc

May 15 • 04:00PM ET

4.25

+0.09 2.16 %

Healthcare • Biotechnology • USA • Micro • NASD

May 14, 8:31 PMMomentum from Q1 earnings beat, manufacturing divestiture, and $202.5M capital infusion drives MGNX ~20-24% surge.

Peers: XNCR ZYME FATE ADCT IOVA

| Held by: VTI VXF IWC DFAS VHT PRFZ AVSC DFMC DCOR BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.11	Insider Own	3.41%	Shs Outstand	63.56M	Perf Week	41.67%
Market Cap	270.14M	Forward P/E	-	EPS next Y	-1.53	Insider Trans	0.00%	Shs Float	61.39M	Perf Month	24.63%
Enterprise Value	221.13M	PEG	-	EPS next Q	-0.08	Inst Own	61.36%	Short Float	4.77%	Perf Quarter	148.54%
Income	-70.36M	P/S	1.72	EPS this Y	-4.15%	Inst Trans	-9.72%	Short Ratio	2.36	Perf Half Y	189.12%
Sales	157.08M	P/B	12.74	EPS next Y	-24.30%	ROA	-31.80%	Short Interest	2.93M	Perf YTD	163.98%
Book/sh	0.33	P/C	1.75	EPS next 5Y	-18.83%	ROE	-140.27%	52W High	4.31 -1.39%	Perf Year	175.97%
Cash/sh	2.43	P/FCF	-	EPS past 3/5Y	15.37% 13.74%	ROIC	-58.05%	52W Low	1.18 258.65%	Perf 3Y	-34.82%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-0.54% 7.35%	Gross Margin	69.93%	Volatility	12.18% 7.74%	Perf 5Y	-85.59%
Dividend TTM	-	EV/Sales	1.41	EPS Y/Y TTM	-25.03%	Oper. Margin	-40.53%	ATR (14)	0.30	Perf 10Y	-75.56%
Dividend Ex-Date	-	Quick Ratio	1.80	Sales Y/Y TTM	1.97%	Profit Margin	-44.79%	RSI (14)	73.87	Recom	2.29
Dividend Gr. 3/5Y	- -	Current Ratio	1.90	EPS Q/Q	11.06%	SMA20	29.61%	Beta	1.16	Target Price	6.75
Payout	-	Debt/Eq	4.96	Sales Q/Q	57.48%	SMA50	33.73%	Rel Volume	1.61	Prev Close	4.16
Employees	293	LT Debt/Eq	4.72	Earnings	May 13 AMC	SMA200	108.43%	Avg Volume	1.24M	Price	4.25
IPO	Oct 10, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.05% 36.30%	Trades		Volume	1,995,106	Change	2.16%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-26	Upgrade	B. Riley Securities	Neutral → Buy	$9
Sep-17-25	Resumed	Barclays	Overweight	$3
Nov-07-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-01-24	Downgrade	BTIG Research	Buy → Neutral
Jul-31-24	Downgrade	Guggenheim	Buy → Neutral
Jul-31-24	Downgrade	B. Riley Securities	Buy → Neutral	$18 → $5
May-10-24	Downgrade	TD Cowen	Buy → Hold
May-10-24	Downgrade	Stifel	Buy → Hold	$29 → $7
May-10-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$24 → $8
Apr-26-24	Initiated	B. Riley Securities	Buy	$25
Apr-09-24	Upgrade	TD Cowen	Hold → Buy
Mar-04-24	Reiterated	BTIG Research	Buy	$12 → $24
Feb-14-24	Downgrade	H.C. Wainwright	Buy → Neutral	$12 → $14
Dec-20-23	Upgrade	Citigroup	Neutral → Buy	$7 → $13
Nov-07-23	Upgrade	Guggenheim	Neutral → Buy	$12
Mar-17-23	Downgrade	Guggenheim	Buy → Neutral
Nov-22-22	Downgrade	Cowen	Outperform → Market Perform
Nov-14-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$5.70 → $16
Jul-18-22	Downgrade	SMBC Nikko	Outperform → Neutral	$5
Jul-11-22	Downgrade	BMO Capital Markets	Outperform → Market Perform	$31 → $4

Show Previous Ratings

May-14-26 04:01PM	MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum (GlobeNewswire) +20.58%
May-13-26 04:26PM	MacroGenics: Q1 Earnings Snapshot (Associated Press)
04:01PM	MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation (GlobeNewswire)
May-12-26 11:08AM	GMP Manufacturing Sale Gives MacroGenics Additional Non-Dilutive Capital for Pipeline Development (MGNX) (InvestorsHub) +19.32%
May-11-26 05:20PM	MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals (GlobeNewswire)
07:30AM	Loading…
May-04-26 07:30AM	MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ Royalty Purchase Agreement (GlobeNewswire)
Apr-08-26 04:30PM	FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study (GlobeNewswire)
Mar-09-26 05:15PM	MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.83% +45.34%
04:23PM	MacroGenics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures (GlobeNewswire)
Feb-26-26 06:00PM	BioLife Solutions, Inc. (BLFS) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
05:30PM	MacroGenics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-24-26 06:16AM	Why Is MacroGenics Stock Sinking Tuesday? (Benzinga)
Feb-23-26 06:14PM	MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial (GlobeNewswire)
Jan-13-26 09:19AM	Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes (Zacks)
10:26AM	Loading…
Jan-05-26 10:26AM	FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children (Zacks) +6.83%
Nov-25-25 04:05PM	MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-12-25 05:15PM	MacroGenics (MGNX) Q3 Earnings and Revenues Surpass Estimates (Zacks) +8.84%
04:07PM	MacroGenics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress (GlobeNewswire)
Nov-10-25 09:55AM	MacroGenics (MGNX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Nov-06-25 04:30PM	MacroGenics to Participate in the Stifel 2025 Healthcare Conference (GlobeNewswire) -5.56%
Oct-30-25 05:30PM	Stryker (SYK) Q3 Earnings and Revenues Beat Estimates (Zacks) -5.62%
Sep-02-25 04:30PM	MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +9.77%
Aug-14-25 05:15PM	MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:10PM	MacroGenics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities (GlobeNewswire)
Aug-13-25 04:01PM	MacroGenics Appoints Eric Risser as President and Chief Executive Officer (GlobeNewswire) +12.93%
08:50AM	OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Jul-31-25 07:25AM	SNDL Inc. (SNDL) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
05:10PM	Loading…
Jul-29-25 05:10PM	AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.39%
Jun-10-25 07:00AM	MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ Royalty Purchase Agreement (GlobeNewswire) +8.54%
Jun-03-25 04:30PM	MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (GlobeNewswire) +8.63%
May-22-25 09:36AM	Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies (Zacks) +6.04%
May-21-25 11:37AM	4 Medical Product Stocks to Watch From a Challenging Industry (Zacks) -5.10%
May-13-25 05:15PM	MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:11PM	MacroGenics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results (GlobeNewswire)
May-12-25 09:46AM	What To Expect From Macrogenics Inc (MGNX) Q1 2025 Earnings (GuruFocus.com) +11.19%
07:15AM	Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 07:40AM	Owens & Minor (OMI) Q1 Earnings Top Estimates (Zacks)
May-07-25 05:40PM	Biote Corp. (BTMD) Q1 Earnings and Revenues Surpass Estimates (Zacks)
May-06-25 04:30PM	MacroGenics Announces Date of First Quarter 2025 Financial Results (GlobeNewswire) -10.37%
May-01-25 04:30PM	MacroGenics to Participate in Upcoming Investor Conference (GlobeNewswire)
Apr-17-25 08:52AM	4 Medical Product Stocks to Buy From a Challenging Industry (Zacks) +6.78%
Apr-03-25 09:35AM	MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.74%
Mar-21-25 02:19PM	MacroGenics axes ADC drug following Phase II failure in prostate cancer (Clinical Trials Arena)
12:05PM	Macrogenics Inc (MGNX) Q4 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
09:29AM	Q4 2024 MacroGenics Inc Earnings Call (Thomson Reuters StreetEvents)
03:05AM	Macrogenics Inc (MGNX) Q4 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses (GuruFocus.com)
Mar-20-25 08:15PM	MacroGenics (MGNX) Q4 2024 Earnings Call Transcript (Motley Fool)
07:09PM	MacroGenics, Inc. (MGNX) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:00PM	MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:50PM	MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:02PM	MacroGenics Provides Update on Corporate Progress and 2024 Financial Results (GlobeNewswire)
10:00AM	Here are the major earnings after the close today (SeekingAlpha)
Mar-19-25 05:35PM	MacroGenics FY 2024 Earnings Preview (SeekingAlpha) +6.34%
05:15PM	Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-06-25 07:30AM	MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call (GlobeNewswire)
Feb-27-25 07:30AM	MacroGenics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Dec-02-24 04:30PM	MacroGenics to Participate in Upcoming Investor Conference (GlobeNewswire) -6.78%
Nov-06-24 04:30PM	MacroGenics to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.14% +6.44%
08:51AM	Q3 2024 MacroGenics Inc Earnings Call (Thomson Reuters StreetEvents)
02:25AM	Macrogenics Inc (MGNX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Developments (GuruFocus.com)
Nov-05-24 10:15PM	MacroGenics (MGNX) Q3 2024 Earnings Call Transcript (Motley Fool)
08:00PM	Here's What Key Metrics Tell Us About MacroGenics (MGNX) Q3 Earnings (Zacks)
07:30PM	MacroGenics (MGNX) Beats Q3 Earnings and Revenue Estimates (Zacks)
06:26PM	MacroGenics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-04-24 07:13AM	Earnings To Watch: Macrogenics Inc (MGNX) Reports Q3 2024 Result (GuruFocus.com)
Oct-30-24 07:30AM	MacroGenics Announces Leadership Transition (GlobeNewswire)
Oct-29-24 04:30PM	MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call (GlobeNewswire) -5.11%
Oct-23-24 08:41AM	TerSera acquires global rights to MacroGenics' MARGENZA for breast cancer treatment (Pharmaceutical Business Review)
Oct-22-24 07:30AM	MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA (Business Wire)
Sep-24-24 05:45AM	MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGNX (PR Newswire)
Sep-23-24 11:05AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile) -6.71%
Sep-20-24 05:06AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Sep-19-24 01:29PM	MacroGenics, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights MGNX (GlobeNewswire)
Sep-17-24 08:30AM	MacroGenics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MGNX (PR Newswire)
05:45AM	Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX (PR Newswire)
Sep-15-24 03:00AM	MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024 (GlobeNewswire)
Sep-13-24 08:34AM	Do Options Traders Know Something About MacroGenics (MGNX) Stock We Don't? (Zacks)
Sep-11-24 08:30AM	MacroGenics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MGNX (PR Newswire)
Sep-08-24 07:10PM	MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024 (GlobeNewswire)
Sep-04-24 03:29PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Sep-03-24 05:45AM	Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX (PR Newswire) -6.55%
Sep-02-24 02:05PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire)
Aug-30-24 09:43AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Aug-29-24 01:09PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire)
Aug-27-24 10:48AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Aug-26-24 03:40PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire)
Aug-22-24 03:16PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire) -7.50%
01:17PM	MacroGenics, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights MGNX (GlobeNewswire)
Aug-21-24 07:05AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Aug-19-24 04:37PM	MacroGenics (MGNX) Under Fire as Analyst Downgrade Deepens Crisis Hagens Berman (GlobeNewswire) +9.91%
Aug-17-24 03:29PM	Kessler Topaz Meltzer & Check, LLP Encourages MacroGenics, Inc. Investors with Losses to Contact the Firm (GlobeNewswire)
Aug-16-24 05:45AM	MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGNX (PR Newswire)
04:26AM	MacroGenics (MGNX) Under Fire as Analyst Downgrade Deepens Crisis - Hagens Berman (Newsfile)
Aug-15-24 02:19PM	MacroGenics (MGNX) Under Fire as Analyst Downgrade Deepens Crisis Hagens Berman (GlobeNewswire)
Aug-14-24 12:19PM	MacroGenics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights MGNX (GlobeNewswire) -5.38%

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

CEOMr. Eric Blasius Risser

Senior VPMr. James Karrels

Senior VP of Research & Chief Scientific OfficerDr. Ezio Bonvini M.D.

Senior Vice President of Technical OperationsDr. Thomas M. Spitznagel Ph.D.

Senior VPMr. Jeffrey Stuart Peters J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Koenig Scott	Director	Feb 15 '26	Option Exercise	0.00	21,165	0	867,240	Feb 17 06:22 PM
HEIDEN WILLIAM K	Director	Aug 19 '25	Buy	1.52	50,500	76,760	61,500	Aug 21 04:19 PM
HEIDEN WILLIAM K	Director	Aug 20 '25	Buy	1.49	49,500	73,755	111,000	Aug 21 04:19 PM
Koenig Scott	Director	Aug 13 '25	Option Exercise	0.00	52,829	0	830,244	Aug 15 05:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MGNX

Macrogenics Inc

Upgrade your Finviz experience